万赛维要注意什么事项呢？

The tablet is the L-valyl ester (prodrug) of ganciclovir, which is rapidly converted into ganciclovir by esterases in the small intestine and liver after oral administration. Ganciclovir is a synthetic analog of 2’-deoxyguanosine that inhibits herpes virus replication in vitro and in vivo.

You should pay attention to the following aspects when taking Vancevi:

The absolute bioavailability of Vansevir tablets measured as ganciclovir is 10 times higher than that of ganciclovir capsules. Vansevir tablets cannot replace ganciclovir capsules in a 1:1 ratio. Patients who previously took ganciclovir capsules and want to switch to Vancevir tablets should be informed that there is a risk of overdose if they take Vancevir tablets in excess of the prescribed dose.

Monitoring of complete blood count and platelet count is recommended during treatment. For patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, it is recommended to use blood cell growth factor therapy and/or consider suspending medication. For patients with renal insufficiency, the dose needs to be adjusted based on creatinine clearance.

Convulsions, sedation, dizziness, ataxia, and/or confusion have been reported after administration of Vancevir and/or cyclovir. If these conditions occur, they may affect activities that require concentration, including the patient's ability to drive a car and operate machinery.

In addition, pay attention to drug-drug interactions. Convulsions have been reported in patients receiving imipenem-cilastatin (Tylon) and ganciclovir concomitantly. Vancevir should not be taken with Tylenol unless the possible benefits outweigh the potential risks.

Both Zidovudine and Vancevir tablets may cause neutropenia and anemia when used alone. Some patients may not tolerate the full dose of these two drugs.

Plasma concentrations of didanosine may be increased when coadministered with tablets; therefore, patients should be closely monitored for didanosine toxicity. Concomitant use of Vancevi tablets with other drugs known to be bone marrow suppressive or associated with renal insufficiency may result in increased toxicity.